Cytokinetics Inc. (cytk 3.5 07/01/27)
13F holders, Q2 2024 (June 30)5holders −2
0new positions
2sold out
$8.89avg. 13F price*
At the end of Q2 2024, 5 institutions reported holding Cytokinetics Inc. (cytk 3.5 07/01/27) in their 13F filings, down 2 from Q1 2024. 0 opened new positions and 2 sold out. The largest holders were Boussard & Gavaudan Investment Management LLP ($7.8M), Nomura Holdings Inc. ($7.5M) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($2.0M).
- Company
- Cytokinetics Inc. (cytk 3.5 07/01/27)
- CUSIP
- 23282WAC4
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $3.1M |
All 13F filers, Q1 2024 → Q2 2024: 131,913 shares bought and 6,814,759 shares sold, net −6,682,846 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Boussard & Gavaudan Investment Management LLP | 2.47% | Reduce -5.7% | 5,991 | $7.8M |
| Nomura Holdings Inc. | 0.05% | Add +2296.1% | 137,658 | $7.5M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | No change | 1,500,000 | $2.0M |
| Bank of New York Mellon Corp | 0.00% | No change | 200,000 | $262K |
| Jane Street Group, LLC | 0.00% | Reduce -97.3% | 147,000 | $190K |
"% of holder's portfolio" is CYTOKINETICS INC (CYTK 3.5 07/01/27)'s weight in each manager's 13F, not the share of Cytokinetics Inc. (cytk 3.5 07/01/27) the manager owns.